Ropes & Gray represented Georgiamune Inc. in its exclusive worldwide license and collaboration agreement with The Menarini Group for GIM-621, a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. The agreement was announced on October 22.
Georgiamune is a clinical-stage biotechnology company centered on the discovery of novel mechanisms governing immune activation, suppression and homeostasis and leveraging those insights to develop first-in-class therapies designed to reprogram immune signaling pathways to treat cancer and autoimmune disease.
The Ropes & Gray team was led by life sciences licensing partner Abby Gregor and associate Ian Nilsen.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.